NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D plus T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.

被引：0
|
作者：
Long, Georgina V.
Carlino, Matteo S.
Au-Yeung, George
Spillane, Andrew John
Shannon, Kerwin Frank
Gyorki, David E.
Howle, Julie R.
Ch'ng, Sydney
Gonzalez, Maria
Saw, Robyn P. M.
Pennington, Thomas
Lo, Serigne N.
Scolyer, Richard A.
Menzies, Alexander M.
机构：
[1] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[2] Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
[4] Melanoma Inst Australia, Sydney, NSW, Australia
[5] Univ Sydney, Melanoma Inst Australia, Chris OBrien Lifehouse, Sydney, NSW, Australia
[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[7] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[8] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Chris OBrien Life house, Sydney, NSW, Australia
[9] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Mater Hosp Sydney, Sydney, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Univ Sydney, Melanoma Inst Australia, Fac Med & Hlth, Charles Perkins Ctr,Royal Prince Alfred Hosp, Sydney, NSW, Australia
[12] NSW Hlth Pathol, Sydney, NSW, Australia
[13] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[14] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9503
引用
收藏
页数：1
相关论文
共 11 条
  • [1] A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D plus T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)
    Gonzalez, M.
    Menzies, A. M.
    Saw, R.
    Thompson, J. F.
    Spillane, A. J.
    Howle, J.
    Nieweg, O.
    Shannon, K.
    Ch'Ng, S.
    Stretch, J. F.
    Carlino, M. S.
    Guminski, A.
    Emmett, L.
    Rizos, H.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage IIIB/C BRAF V600 mutant melanoma
    Menzies, A. M.
    Gonzalez, M.
    Guminski, A.
    Nieweg, O.
    Shannon, K.
    Thompson, J. F.
    Kefford, R.
    Ch'Ng, S.
    Stretch, J.
    Spillane, A. J.
    Lee, J.
    Lee, H.
    Kapoor, R.
    Emmett, L.
    Rizos, H.
    Saw, R. P.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D plus T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial)
    Gonzalez, Maria
    Menzies, Alexander M.
    Saw, Robyn
    Spillane, Andrew J.
    Nieweg, Omgo E.
    Shannon, Kerwin F.
    Thompson, John F.
    Howle, Julie R.
    Ch'ng, Sydney
    Stretch, Jonathan
    Osorio, Monica
    Emmett, Louise
    Rizos, Helen
    Guminski, Alexander David
    Carlino, Matteo S.
    Scolyer, Richard A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma
    Ribas, A.
    Hodi, F. S.
    Lawrence, D.
    Atkinson, V.
    Agarwal, S.
    Carlino, M. S.
    Fisher, R.
    Long, G. V.
    Miller, W. H.
    Huang, Y.
    Moreno, B. Homet
    Ibrahim, N.
    Hamid, O.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
    Ascierto, P. A.
    Ferrucci, P. F.
    Stephens, R.
    Del Vecchio, M.
    Atkinson, V.
    Schmidt, H.
    Schachter, J.
    Queirolo, P.
    Long, G. V.
    Di Giacomo, A. M.
    Svane, I.
    Lotem, M.
    Bar-Sela, G.
    Couture, F.
    Mookerjee, B. P.
    Ghori, R.
    Ibrahim, N.
    Moreno, B. Homet
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 442 - 442
  • [6] Dabrafenib plus trametinib (D plus T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification
    Larkin, James M. G.
    Hauschild, Axel
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Chiarion-Sileni, Vanna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF-mutant melanoma
    Schadendorf, Dirk
    Hauschild, Axel
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Chiarion-Sileni, Vanna
    Larkin, James M. G.
    Nyakas, Marta
    Dutriaux, Caroline
    Haydon, Andrew
    Mortier, Laurent
    Robert, Caroline
    Schachter, Jacob
    Ji, Ran
    Aimone, Paola
    Manson, Stephanie
    Kefford, Richard
    Dummer, Reinhard
    Kirkwood, John M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Novel Neoadjuvant Targeted Therapy Trial with Dabrafenib plus Trametinib Yields High Response Rates and Improved Relapse-Free Survival Over Standard of Care (SOC) Therapy in Patients with High-risk Resectable BRAF-Mutant Melanoma
    Prieto, P. A.
    Amaria, R.
    Reuben, A.
    Gopalakrishnan, V.
    Spencer, C.
    Jiang, H.
    Zhang, J.
    Tetzlaff, M.
    Lazar, A.
    Burton, E.
    Woodman, S.
    Hwu, P.
    Hwu, W.
    Patel, S.
    Tawbi, H.
    Davies, M.
    Diab, A.
    Glitza, I.
    Bassett, R.
    Cormier, J.
    Gershenwald, J.
    Lee, J. E.
    Lucci, A.
    Royal, R.
    Ross, M.
    Wargo, J. A.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S7 - S7
  • [9] Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib plus trametinib (D plus T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.
    Wargo, Jennifer Ann
    Amaria, Rodabe Navroze
    Prieto, Peter A.
    Andrews, Miles Cameron
    Tetzlaff, Michael T.
    Futreal, Phillip Andrew
    Hwu, Patrick
    Hwu, Wen-Jen
    Glitza, Isabella Claudia
    Tawbi, Hussein Abdul -Hassan
    Cormier, Janice N.
    Lee, Jeffrey Edwin
    Patel, Sapna Pradyuman
    Simpson, Lauren
    Burton, Elizabeth M.
    Bassett, Roland L.
    Ross, Merrick I.
    Gershenwald, Jeffrey E.
    Davies, Michael A.
    Woodman, Scott Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
    Long, G. V.
    Hauschild, A.
    Santinami, M.
    Atkinson, V. G.
    Mandala, M.
    Chiarion-Sileni, V.
    Larkin, J.
    Robert, C.
    Schadendorf, D.
    Dasgupta, K.
    Shilkrut, M.
    Garrett, J.
    Brase, J. C.
    Kefford, R.
    Kirkwood, J. M.
    Dummer, R.
    ANNALS OF ONCOLOGY, 2018, 29
12